Quick Answer
ARTELO BIOSCIENCES, INC. reported Net Income of -$12.88 million for fiscal year 2025.
ARTELO BIOSCIENCES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$12.88M -31.1% |
-$9.83M -5.8% |
-$9.29M +7.9% |
-$10.08M -35.6% |
-$7.44M -59.8% |
-$4.66M -114.3% |
| Diluted EPS | -$12.52 +31.6% |
-$18.30 -482.8% |
-$3.14 | — | — | — |
| Total Assets | $2.80M -40.4% |
$4.70M -64.0% |
$13.04M -36.1% |
$20.42M +61.6% |
$12.63M +188.7% |
$4.38M -32.5% |
| Cash and Equivalents | — | — | — | — | $6.63M +209.5% |
$2.14M -51.6% |
| Stockholders Equity | -$1.27M -144.5% |
$2.86M -75.7% |
$11.75M -39.4% |
$19.40M +61.1% |
$12.04M +210.8% |
$3.88M -29.0% |
| R&D Expense | $5.42M -9.5% |
$5.99M +5.2% |
$5.70M +31.7% |
$4.32M +52.3% |
$2.84M +47.9% |
$1.92M +75.7% |
| Operating Income | -$11.40M -12.8% |
-$10.11M -1.8% |
-$9.93M +3.5% |
-$10.29M -38.2% |
-$7.44M -58.8% |
-$4.69M -46.0% |
| Shares Outstanding | 2.02M +255.7% |
567,582 -82.2% |
3.19M +11.7% |
2.86M +74.6% |
1.64M -67.2% |
4.99M +48.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$3.12M | -175.6% | +3.1% |
| Diluted EPS | September 30, 2025 | -$3.97 | -89.0% | +29.2% |
| Total Assets | September 30, 2025 | $4.27M | -40.2% | -2.1% |
| Cash and Equivalents | September 30, 2022 | $7.14M | — | -41.1% |
| Stockholders Equity | September 30, 2025 | -$633.0K | -110.0% | +55.0% |
| R&D Expense | September 30, 2025 | $1.27M | +292.3% | -31.9% |
| Operating Income | September 30, 2025 | -$3.09M | -158.5% | +1.9% |
| Shares Outstanding | September 30, 2025 | 1.56M | -51.8% | +120.8% |
- ARTELO BIOSCIENCES, INC. reported Net Income of -$12.88 million for fiscal year 2025.
- ARTELO BIOSCIENCES, INC. showed a decrease of -31.1% in Net Income compared to the prior fiscal year.
- ARTELO BIOSCIENCES, INC. reported Diluted EPS of $12.52 per share (loss) for fiscal year 2025.
- ARTELO BIOSCIENCES, INC. showed an increase of +31.6% in Diluted EPS compared to the prior fiscal year.
- ARTELO BIOSCIENCES, INC. reported Total Assets of $2.80 million for fiscal year 2025.
- ARTELO BIOSCIENCES, INC. showed a decrease of -40.4% in Total Assets compared to the prior fiscal year.
- ARTELO BIOSCIENCES, INC. reported Cash and Equivalents of $6.63 million for fiscal year 2021.
- ARTELO BIOSCIENCES, INC. showed an increase of +209.5% in Cash and Equivalents compared to the prior fiscal year.
- ARTELO BIOSCIENCES, INC. reported Stockholders Equity of -$1.27 million for fiscal year 2025.
- ARTELO BIOSCIENCES, INC. showed a decrease of -144.5% in Stockholders Equity compared to the prior fiscal year.
- ARTELO BIOSCIENCES, INC. reported R&D Expense of $5.42 million for fiscal year 2025.
- ARTELO BIOSCIENCES, INC. showed a decrease of -9.5% in R&D Expense compared to the prior fiscal year.
- ARTELO BIOSCIENCES, INC. reported Operating Income of -$11.40 million for fiscal year 2025.
- ARTELO BIOSCIENCES, INC. showed a decrease of -12.8% in Operating Income compared to the prior fiscal year.
- ARTELO BIOSCIENCES, INC. reported Shares Outstanding of 2.02 million shares for fiscal year 2025.
- ARTELO BIOSCIENCES, INC. showed an increase of +255.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: